肝积颗粒合介入治疗原发性肝癌的临床观察

目的：观察肝积颗粒合介入治疗原发性肝癌气虚血瘀证的临床疗效。方法：将符合研究条件的患者随机分为治疗组（30例）和对照组（30例），分别采用肝积颗粒保介入治疗和单纯介入治疗，观察两组的近期临床疗效、远期生存时间以及T细胞亚群、AFP值的变化情况。结果：治疗组瘤体缓解率为20．00％、稳定率为90．00％，对照组分别为16．67％、63．33％，其中，瘤体稳定率两组差异有显著性（P＜0．05），治疗组在减轻临床症状，延长生存时间、升高CD3、CD4值等方面优于对照组（P＜0．05），两组AFP值变化比较，差异无显著性。结论：肝积颗粒联合介入治疗原发性肝癌气虚血瘀证，可提高临床疗效，改善临床症状，增强机体免疫功能，延长生存期。

CLINICAL OBSERVATION ON TREATMENT OF PRIMARY LIVER CANCER WITH GANJI GRANULE COMBINED WITH TACE

Objective:To observe the clinical effect of Ganji granule combined with transcatheter arterial chemoembolization(TACE) in treating Qi deficiency-blood stasis syndrome of primary liver cancer. Method: 60 patients with study conditions were randomly divided into the treatment group (30 cases) treated by Ganji granule combined with TACE, and the control group(30 cases) by TACE alone. The recent clinical effect, remote survival time, T lymphocyte subsets and the AFP level were observed in the two groups. Result: The tumor remission rate was 20.00% in treatment group and 16.67% in control group,the tumor stable rate was 90.00% in treatment group and 63.33% in control group, and the difference between the two groups was statistically significant (P<0.05).The treatment group was better than the control group in relieving clinical symptoms,prolonging survival time, raising CD_3,CD_4 level(P<0.05).But thee was no significant difference between the two groups in the AFP level. Conclusion: Ganji granule in combination with TACE for primary liver cancer could improve the clinical effect, relieve clinical symptoms, raise immunologic functions and prolong survival time.